Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers from the Nuffield Department of Population Health, in collaboration with the Royal College of Obstetricians and Gynaecologists, the Universities of Leeds and Birmingham, Kings and Imperial Colleges London, have published new research that suggests pregnant women are no more likely to become ill with severe COVID-19 than non-pregnant woman. However, the majority of women who did become severely ill were in their third trimester of pregnancy, emphasising the importance of social distancing for this group.

The study, published today as a pre-print, looked at 427 pregnant women admitted to hospitals in the UK between 1 March and 14 April 2020 with confirmed COVID-19 (4.9 women out of every 1000 pregnant women, suggesting pregnant women are not at a higher risk of experiencing severe illness). Information for the study was collected from all 194 hospitals in the UK with a consultant-led maternity unit.

Pregnant women from black and ethnic minority backgrounds were more likely to be admitted to hospital for COVID-19. This inequality persisted even when women from London, the West Midlands and the North West were excluded from the analysis, meaning the difference cannot be explained by higher rates of COVID-19 infection in those areas.

The analysis also showed that older pregnant women, those who were overweight or obese, and pregnant women who had pre-existing medical problems, such as high blood pressure and diabetes, were more likely to be admitted to hospital with the infection. Women who were admitted to hospital with COVID-19 in pregnancy were less likely to smoke than a group of comparison pregnant women.

Read the full story on the Nuffield Department of Population Health website

The story is also featured on the University of Oxford website

Similar stories

PRINCIPLE Covid-19 treatments trial widens to under 50s and adds colchicine

Clinical Trials Coronavirus COVID-19 General Research

From today, the UK’s national priority platform trial of Covid-19 treatments for recovery at home launches its investigation of the gout drug colchicine, and expands for the first time to include adults of any age.

Regular meat consumption linked with a wide range of common diseases

Research

Regular meat consumption is associated with a range of diseases that researchers had not previously considered, according to a large, population-level study conducted by a team at the University of Oxford.

New data show vaccines reduce severe COVID-19 in older adults

Coronavirus COVID-19 Research

New data show both Oxford / AstraZeneca vaccine and the Pfizer-BioNTech vaccines significantly reduce severe COVID-19 in older adults.

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.